JP2018515557A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515557A5 JP2018515557A5 JP2017560314A JP2017560314A JP2018515557A5 JP 2018515557 A5 JP2018515557 A5 JP 2018515557A5 JP 2017560314 A JP2017560314 A JP 2017560314A JP 2017560314 A JP2017560314 A JP 2017560314A JP 2018515557 A5 JP2018515557 A5 JP 2018515557A5
- Authority
- JP
- Japan
- Prior art keywords
- esketamine
- pharmaceutical composition
- composition according
- during
- dosage unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims description 54
- 229960000450 esketamine Drugs 0.000 claims description 54
- 230000006698 induction Effects 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 28
- 238000012423 maintenance Methods 0.000 claims description 20
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000902 placebo Substances 0.000 claims description 2
- 229940068196 placebo Drugs 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164026P | 2015-05-20 | 2015-05-20 | |
| US62/164,026 | 2015-05-20 | ||
| PCT/US2016/033404 WO2016187491A1 (en) | 2015-05-20 | 2016-05-20 | Methods and kits for treating depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018515557A JP2018515557A (ja) | 2018-06-14 |
| JP2018515557A5 true JP2018515557A5 (https=) | 2019-06-13 |
Family
ID=57320901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560314A Pending JP2018515557A (ja) | 2015-05-20 | 2016-05-20 | うつ病を治療するための方法及びキット |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20160338977A1 (https=) |
| EP (1) | EP3297618A4 (https=) |
| JP (1) | JP2018515557A (https=) |
| KR (1) | KR20180008634A (https=) |
| CN (1) | CN107735081A (https=) |
| AU (3) | AU2016263598A1 (https=) |
| CA (1) | CA2986477A1 (https=) |
| CL (1) | CL2017002904A1 (https=) |
| CO (1) | CO2017011564A2 (https=) |
| DO (1) | DOP2017000268A (https=) |
| EA (1) | EA201792545A1 (https=) |
| EC (1) | ECSP17077930A (https=) |
| GT (1) | GT201700246A (https=) |
| HK (1) | HK1252937A1 (https=) |
| IL (1) | IL255463A (https=) |
| MA (1) | MA42135A (https=) |
| MX (1) | MX2017014797A (https=) |
| PE (1) | PE20180260A1 (https=) |
| PH (1) | PH12017502103A1 (https=) |
| WO (1) | WO2016187491A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| CN106714789A (zh) | 2014-08-13 | 2017-05-24 | 詹森药业有限公司 | 用于治疗抑郁症的方法 |
| CN107208133A (zh) | 2014-09-15 | 2017-09-26 | 詹森药业有限公司 | 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法 |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US11191734B2 (en) | 2015-06-27 | 2021-12-07 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| MX2020006650A (es) | 2017-12-22 | 2020-11-06 | Janssen Pharmaceuticals Inc | Esketamina para el tratamiento de la depresión. |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| JP2021529732A (ja) * | 2018-06-27 | 2021-11-04 | クレキシオ バイオサイエンシーズ エルティーディー． | 大うつ病性障害の処置方法 |
| EP3628313B1 (en) * | 2018-09-28 | 2025-02-12 | Novohale Therapeutics, LLC | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| WO2020070547A1 (en) * | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| KR20210074275A (ko) | 2018-10-05 | 2021-06-21 | 클렉시오 바이오사이언시스 리미티드 | 주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법 |
| WO2020070706A1 (en) * | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| US12364672B2 (en) | 2018-10-11 | 2025-07-22 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| MX2021010683A (es) * | 2019-03-05 | 2021-12-10 | Janssen Pharmaceuticals Inc | Esketamina para el tratamiento de la depresión. |
| US20220304950A1 (en) * | 2019-08-28 | 2022-09-29 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of patients with major depressive disorder, including suicidality |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| WO2021137147A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| WO2021242504A1 (en) * | 2020-05-28 | 2021-12-02 | Janssen Pharmaceuticals, Inc. | Methods for treating depression |
| GB202019952D0 (en) * | 2020-12-17 | 2021-02-03 | Neurocentrx Pharma Ltd | Novel compositions |
| WO2022235576A1 (en) * | 2021-05-03 | 2022-11-10 | Wang Michael Z | Methods and compositions for treating depression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007111880A2 (en) * | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20110038807A1 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| WO2013003669A2 (en) * | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
| PE20141906A1 (es) * | 2012-03-12 | 2014-12-05 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento |
| EP2830604A4 (en) * | 2012-03-30 | 2015-08-19 | Gen Hospital Corp | COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS |
| JP6462663B2 (ja) * | 2013-04-12 | 2019-01-30 | アイカーン スクール オブ メディシン アット マウント シナイ | 心的外傷後ストレス障害を処置するための方法 |
| CN107208133A (zh) * | 2014-09-15 | 2017-09-26 | 詹森药业有限公司 | 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法 |
-
2016
- 2016-05-19 US US15/159,257 patent/US20160338977A1/en not_active Abandoned
- 2016-05-20 CA CA2986477A patent/CA2986477A1/en not_active Abandoned
- 2016-05-20 CN CN201680029082.XA patent/CN107735081A/zh active Pending
- 2016-05-20 JP JP2017560314A patent/JP2018515557A/ja active Pending
- 2016-05-20 MX MX2017014797A patent/MX2017014797A/es unknown
- 2016-05-20 EP EP16797348.6A patent/EP3297618A4/en not_active Withdrawn
- 2016-05-20 EA EA201792545A patent/EA201792545A1/ru unknown
- 2016-05-20 PE PE2017002425A patent/PE20180260A1/es unknown
- 2016-05-20 MA MA042135A patent/MA42135A/fr unknown
- 2016-05-20 AU AU2016263598A patent/AU2016263598A1/en not_active Abandoned
- 2016-05-20 WO PCT/US2016/033404 patent/WO2016187491A1/en not_active Ceased
- 2016-05-20 KR KR1020177036002A patent/KR20180008634A/ko not_active Withdrawn
- 2016-05-20 HK HK18112292.0A patent/HK1252937A1/zh unknown
-
2017
- 2017-11-06 IL IL255463A patent/IL255463A/en unknown
- 2017-11-14 CO CONC2017/0011564A patent/CO2017011564A2/es unknown
- 2017-11-15 CL CL2017002904A patent/CL2017002904A1/es unknown
- 2017-11-16 GT GT201700246A patent/GT201700246A/es unknown
- 2017-11-17 DO DO2017000268A patent/DOP2017000268A/es unknown
- 2017-11-20 PH PH12017502103A patent/PH12017502103A1/en unknown
- 2017-11-23 EC ECIEPI201777930A patent/ECSP17077930A/es unknown
-
2021
- 2021-08-11 AU AU2021215155A patent/AU2021215155A1/en not_active Abandoned
-
2023
- 2023-09-25 AU AU2023237026A patent/AU2023237026A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515557A5 (https=) | ||
| JP2017528483A5 (https=) | ||
| JP2020002171A5 (https=) | ||
| JP2018138603A5 (https=) | ||
| JP2017503820A5 (https=) | ||
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| JP2016540738A5 (https=) | ||
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| EA201490748A1 (ru) | Лечение рассеянного склероза комбинацией лахинимода и финголимода | |
| JP2015187125A5 (https=) | ||
| JP2017529382A5 (https=) | ||
| EA201990558A2 (ru) | ДОСТАВКА НАЦЕЛЕННЫХ НА ЭКЗОН 2 ПОЛИНУКЛЕОТИДНЫХ КОНСТРУКЦИЙ U7snRNA ПРИ ПОМОЩИ РЕКОМБИНАНТНОГО АДЕНОАССОЦИИРОВАННОГО ВИРУСА | |
| NO20091826L (no) | Fremgangsmater for dosering av oralt aktive 1,2,4-oksadiazol for nonsense mutasjonsuppresjonsterapi | |
| JP2015505564A5 (https=) | ||
| JP2019501886A5 (https=) | ||
| JP2017160178A5 (https=) | ||
| JP2017513809A5 (https=) | ||
| EA202190429A1 (ru) | Биодоступные пероральные дозированные формы | |
| JP2016515137A5 (https=) | ||
| JP2019507786A5 (https=) | ||
| CY1120176T1 (el) | Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης | |
| JP2017524721A5 (https=) | ||
| JP2018505901A5 (https=) | ||
| JP2018505901A (ja) | 統合失調症の治療のためのイロペリドン |